1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Analysis of the Cardiac Biomarker Diagnostics Market 

Analysis of the Cardiac Biomarker Diagnostics Market 

  • September 2015
  • -
  • Frost & Sullivan
  • -
  • 116 pages

Summary

Table of Contents

Analysis of the Cardiac Biomarker Diagnostics Market 

Key Findings

The overall US cardiac biomarker diagnostic market stands at $ million in 2014 and is predicted to grow to $ million by 2021 at a compound annual growth rate (CAGR) of %.

- The increasing adoption of point-of-care tests (POCTs) in the United States makes this segment the fastest growing, where it holds close to % of the cardiac biomarker market.

- There is an increasing number of publications discussing the importance of POCT in improving patient outcomes. This is spurring adoption rate at a clinical and ambulatory level.

- The POCT market for cardiac biomarkers is spurring the growth in this region.

- With the implementation of Affordable Care Act (ACA), there is a shift toward value-based care. This is increasing pressure on manufacturers to produce more cost efficient and efficient devices for consumers, especially in the hospital sector.

- Manufacturers are seeing the value of integrated and wholesome platform solutions in this emerging value-based system.

- Device companies like Medtronic are entering the cardiac space to provide telehealth solutions to patients. Siemens and Roche have a unique advantage due to their strong affiliation with their medical devices and pharmaceutical wings, respectively.

- Companies with different diagnostic wings have a unique advantage, as they can offer a more integrated solution to diagnose a patient.

- Still in the early stages, the cardiovascular segment has tremendous potential for personalized medicine. There is a movement toward this space similar to other fields, like oncology.

- In the future, heart failure therapy is going to utilize a combination of multiple markers for risk assessment and diagnosis. Many of these biomarker tests are going to combine into a panel test rather than compete individually.

- Products with a narrow therapeutic index, which can be dangerous either over- or underdosing, have a higher profitability capacity to develop companion diagnostic tests to determine sensitivity to the product.

- Companion diagnostics is a major opportunity for manufacturers as cardiovascular disease holds only % of the overall companion diagnostics market space.

- Integrating digital apps enables manufacturers to understand consumer behavior but also provide differentiated products compared to competitors.

- Manufacturers can begin to offer consultations and services for biomarker testing and not be exclusive to providing lab solutions.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2017 Europe Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

2017 Europe Cancer Diagnostics Market: Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities

  • $ 36000
  • Industry report
  • February 2017
  • by Venture Planning Group

This new 31-country report from VPGMarketResearch.com is available by country, market segment, section, or individual test. This report is designed to assist diagnostics industry executives, as well as ...

2017 Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

2017 Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Cancer Diagnostics 2021: Supplier Shares and Strategies, Country Segment Forecasts, Tehnology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2021: Supplier Shares and Strategies, Country Segment Forecasts, Tehnology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • March 2017
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...


Download Unlimited Documents from Trusted Public Sources

Diagnostics Forecast in the US

  • March 2017
    2 pages
  • United States  

View report >

Diagnostics Markets in the US

  • March 2017
    3 pages
  • Diagnostics  

  • United States  

View report >

Diagnostics Forecast in the US

  • February 2017
    2 pages
  • Diagnostics  

    Cancer  

    Health Care Pro...  

  • United States  

View report >

Related Market Segments :

Diagnostics
Biomarker

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.